MedTrace Logo

Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers

NCT04225052 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-01-23

No results posted yet for this study

Summary

A randomized, open-label, single dose, crossover clinical trial to evaluate the safety and pharmacokinetics of YHP1903 in healthy volunteers

Conditions

  • Healthy Volunteer

Interventions

DRUG

YHP1903

YHP1903 Tab. 1mg

DRUG

Champix

Comparator Champix Tab. 1mg

Sponsors & Collaborators

  • Chonbuk National University Hospital

    collaborator OTHER

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Mingul Kim, PhD · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-19
Primary Completion
2020-01-08
Completion
2020-01-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04225052 on ClinicalTrials.gov